Hubbry Logo
EnzyteEnzyteMain
Open search
Enzyte
Community hub
Enzyte
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Enzyte
Enzyte
Enzyte
View on Wikipedia
from Wikipedia

Enzyte is an American herbal nutritional supplement originally manufactured by Berkeley Premium Nutraceuticals. The marketing of Enzyte resulted in a conviction and prison term for the company's owner and bankruptcy of the company. The product is now marketed by Vianda, LLC of Cincinnati, Ohio. The manufacturer has claimed that Enzyte promotes "natural male enhancement," which is a euphemism for enhancing erectile function. However, its effectiveness has been called into doubt and the claims of the manufacturer have been under scrutiny from various state and federal organizations. Kenneth Goldberg, medical director of the Male Health Center at Baylor University, says, "It makes no sense medically. There's no way that increasing blood flow to the penis, as Enzyte claims to do, will actually increase its size."[1]

In March 2005, following thousands of consumer complaints to the Better Business Bureau, federal agents raided Berkeley facilities, gathering material that resulted in a 112-count criminal indictment. The company's founder and CEO, Steven M Warshak, and his mother, Harriet Warshak, were found guilty of conspiracy to commit mail fraud, bank fraud, and money laundering, and in September 2008 they were sentenced to prison and ordered to forfeit $500 million in assets.[2] The convictions and fines forced the company into bankruptcy, and in December 2008 its assets were sold for $2.75 million to investment company Pristine Bay, which continued operations.[3]

Enzyte is widely advertised on U.S. television as "The once-daily tablet for natural male enhancement", or "The one-a-day tablet for natural male enhancement." The commercials feature a character known as "Smilin' Bob," acted out by Canadian actor Andrew Olcott,[4] who, in the commercials, always wears a smile that is implied to result from the enhancing effects of Enzyte; these advertisements feature double entendres. Some such commercials also feature an equally smiling "Mrs. Bob."

Because Enzyte is an herbal product, no testing is required by the U.S. Food and Drug Administration. An official of the Federal Trade Commission division that monitors advertising says the lack of scientific testing is "a red flag right away. There's no science behind these claims."[5] The company has conceded that it has no scientific studies that substantiate any of its Enzyte claims.[6]

Ira Sharlip, a spokesman for the American Urological Association, has said, "There is no such thing as a penis pill that works. These are all things that are sold for profit. There's no science or substance behind them."[5]

Ingredients

[edit]

Enzyte's formulation was reportedly developed for Vianda by Marilyn Barrett.[citation needed]

Enzyte is said to contain:[citation needed]

Most of the above ingredients are commonly available as over the counter herbal or dietary supplements, and most have anecdotal reports, but marginal or unproven scientific evidence, of efficacy on various systems in the human body. Several of the herbal ingredients are included only in very low quantities.

Yohimbe was previously included in the original formulation of Enzyte, produced until at least 2004.[citation needed] However, as yohimbe's legal status in Canada is unclear, Enzyte produced after 2004 no longer contains yohimbe extract.

Additionally, zinc is an ingredient in Enzyte. Some men who have low zinc levels in their body have had success using zinc supplements to treat erection problems.[7]

Effectiveness

[edit]

Currently, the effectiveness of Enzyte is unproven.

A civil lawsuit alleged Enzyte does not work as advertised.[8] Despite manufacturer claims that Enzyte will increase penis size, girth, and firmness and improve sexual performance, there exists no scientific evidence that Enzyte is capable of making good on these claims. In fact, Enzyte has never been scientifically tested by the FDA or other independent third party.[9] Accordingly, Enzyte is required by current U.S. law to be marketed as an herbal supplement and may not legally be called a drug. In keeping with FTC rulings, Enzyte is not allowed to claim these benefits in its advertising. However, as of June 2010, TV commercials for the product still use the phrase "natural male enhancement."

Federal indictment and trial

[edit]

Thousands of consumer complaints were made to the Better Business Bureau about the company's business practices, especially the "autoship" program that repeatedly charged customers' credit cards for refills even after they canceled their orders. Federal agents raided Berkeley facilities in March 2005, gathering material that led to criminal charges. On September 21, 2006, Berkeley Premium Nutraceuticals; its owner and president, Steve Warshak; and five other individuals were indicted by the United States, Southern District of Ohio, U.S. Attorney Greg Lockhart, on charges of conspiracy, money laundering, and mail, wire, and bank fraud. The indictment alleged that the company defrauded consumers and banks of US$100 million.[2][10] The United States Food and Drug Administration, Internal Revenue Service, United States Postal Inspection Service, and other agencies participated in the investigation.[11] The federal fraud trial began on January 8, 2008.[12]

In testimony during the trial, a former executive with Berkeley testified that the enhancements the company claimed were achieved by use of Enzyte were fabricated, and the company defrauded customers by continuing to charge them for additional shipments of the supplement. He further testified that company employees were instructed to make it as difficult as possible for unhappy customers to receive refunds.[13]

Conviction and sentencing

[edit]

On February 22, 2008, Steven Warshak was found guilty of 93 counts of conspiracy, fraud, and money laundering. On August 27, 2008, he was sentenced by U.S. District Judge Arthur Spiegel to 25 years in prison and ordered to pay $93,000 in fines. Warshak was an inmate at the Federal Correctional Institution in Elkton, Ohio. His company, Berkeley Premium Nutraceuticals, along with other defendants, was ordered to forfeit $500 million. His 75-year-old mother, Harriet Warshak, was sentenced to two years in prison[14][15] but released on bond pending appeal after turning over her house, bank accounts, and other assets related to her crimes.[16]

Both Steven and Harriet Warshak appealed their convictions. The United States Court of Appeals for the Sixth Circuit in United States v. Warshak (6th Cir. December 14, 2010) 631 F.3d 266, upheld Steven Warshak's convictions and all convictions against Harriet Warshak except for money laundering and vacated their sentences, remanding the sentencing to the lower court.

On September 21, 2011, Steven Warshak's sentence was reduced from 25 years to 10 years.[17] His mother's sentence was reduced from two years to one day, and she never served any time in jail.[18] Factors in reducing the sentence were that the amount of total loss by customers may have been less than $400 million and that the sentences of co-defendants were only two years. Warshak was released from prison on June 14, 2017, according to the Federal Prison Inmate Locator system.

Continued company operation

[edit]

The Warshaks' convictions and fines forced the company into bankruptcy. In December 2008, its assets were acquired from bankruptcy court for $2.75 million by investment company Pristine Bay, which is affiliated with Cincinnati developer Chuck Kubicki. Kubicki said he wanted to save the jobs of the company's 200 employees and retain a major tenant in one of his properties in suburban Cincinnati at Forest Park, Ohio. He said he would change the company name but would keep the brand.[3] In March 2009, Hamilton County commissioners unanimously voted to give a $195,000 property tax break to the company based on projected jobs.[19][20]

On June 26, 2009, the company name was changed to Vianda LLC. In a press release, the company announced plans to expand, hiring as many as 400 additional workers.[21] On December 14, 2009, Cincinnati Business Courier reported employment of 180, revision of sales projections of 400% growth to $120 million downward to an estimated 33% growth to $40 million, management team changes, and continued customer complaints of improper billing.[22]

Company is currently under the leadership of Cheryl Jaeger[23] starting on January 6, 2015[citation needed] and the company is now located at 11260 Cornell Park Drive, Suite 706 Cincinnati, Ohio 45242[24] Company is also connected to the following companies DYNAMIC DIRECT, LLC, ENHANCED LIVING PRODUCTS, LLC, MOVNNON, LLC, PRISTINE BAY, LLC, and LAST SAY, LLC.[citation needed]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Enzyte

View on Grokipedia
from Grokipedia
Enzyte is a marketed as a natural male enhancement product intended to support sexual performance, stamina, and blood flow in men. It is formulated as a once-daily capsule containing a blend of botanicals and nutrients, including Asian ginseng root extract (standardized to 7% ginsenosides), ginkgo leaf extract, , Epimedium sagittatum (horny goat weed) extract, muira puama extract, niacin, , and . Originally manufactured by Berkeley Premium Nutraceuticals, Inc., in , , Enzyte is now produced by Vianda, LLC, and has been available since 2001 as a non-GMO, gluten-free option sold over-the-counter and online for approximately $45 per month supply. Introduced in the early , Enzyte gained prominence through aggressive , including television commercials featuring the character "Smiling Bob," which promoted it as enhancing quality, sexual energy, and without the need for prescription drugs. The product was positioned as a safer alternative to pharmaceuticals for addressing age-related erectile decline, with initial claims suggesting potential increases in size by 1 to 3 inches over eight months, later revised to focus on firmer erections and overall vitality. By 2007, Berkeley reported over 3 million users, generating significant revenue through auto-shipment programs and retail distribution at drugstores. Enzyte's marketing practices drew widespread scrutiny for unsubstantiated health claims and deceptive billing tactics, leading to multiple legal actions. In 2006, Berkeley Premium Nutraceuticals settled with 18 states, including , for $2.5 million in penalties and consumer restitution, agreeing to cease unsupported efficacy claims, disclose auto-shipment terms clearly, and reform practices. In 2006, federal authorities pursued further charges, including a civil by the for misleading advertisements and unauthorized charges exceeding $100 million, and a criminal by the Department of Justice alleging conspiracy to commit . In 2008, company founder Steven Warshak was convicted on 93 counts of fraud and , receiving a 25-year prison sentence and ordered to forfeit hundreds of millions in assets, though his sentence was reduced on appeal and he was released in 2015 after serving approximately seven years. A 2006 class-action settlement provided $4.7 million to affected consumers. Health concerns emerged in 2010 when a clinical study published in Archives of found that Enzyte prolonged the on electrocardiograms by up to 11% (37 milliseconds) in healthy young men, raising risks of potentially fatal arrhythmias, particularly for individuals with pre-existing affecting about 1 in 2,000 people. The exact causative ingredient remains unclear, but niacin and other components were implicated; no abnormal rhythms or prolonged erections were observed, though four participants reported skin flushing. As a under U.S. law, Enzyte is not required to undergo pre-market or testing, prompting warnings from medical experts against its use without physician consultation. Despite these issues, the product remains available as of 2025, reformulated and marketed with emphasis on natural support for cardiovascular and .

Product Overview

Description and Purpose

Enzyte is an herbal marketed for natural enhancement, primarily targeting improvements in sexual performance, quality, and overall vitality in men. It was designed to address age-related erectile decline without positioning itself as a pharmaceutical , instead emphasizing its role as a non-prescription option for enhancing confidence and stamina. Launched in 2001 by Berkeley Premium Nutraceuticals, a Cincinnati-based , Enzyte was introduced as a once-daily capsule intended for regular use rather than on-demand consumption. This formulation aimed to provide sustained benefits for men, particularly those aged 30 to 50 experiencing gradual declines in sexual function, by promoting better blood flow and energy levels. Initial branding for Enzyte included distinctive packaging and advertising elements, such as the "Smilin' Bob" —a cheerful, everyday man depicted in various scenarios to symbolize the product's purported effects on daily life and relationships. This character appeared in and print ads, reinforcing the supplement's focus on subtle, natural improvements in male vitality.

Marketing Claims and Advertising

Enzyte's marketing campaign, launched in 2001 by Berkeley Premium Nutraceuticals, heavily relied on television infomercials featuring the humorous character "Smilin' Bob," a perpetually grinning everyman portrayed by actor Andrew Olcott, who appeared in scenarios suggesting newfound confidence and satisfaction without uttering a word. These ads, created by ad executive Randy Spear, aired on channels like and , portraying Bob in everyday settings such as offices, airports, and bowling alleys to imply the product's transformative effects, quickly becoming iconic for their sly, retro style and contributing to widespread brand recognition. The advertisements promoted Enzyte as a "natural male enhancement" supplement, claiming it delivered bigger, fuller erections, increased stamina, and boosted confidence, with implications of permanent results through consistent daily use of its herbal formula. Early promotions specifically asserted up to a 41% increase in penis size or as much as three inches in length within months, alongside firmer, more satisfying erections that reversed age-related issues, all positioned as a safe, prescription-free alternative to pharmaceuticals like Viagra. Berkeley invested over $125 million in TV advertising by 2004, driving peak daily customer inquiries to 65,000 and generating at least $100 million in annual Enzyte sales that year. Distribution channels emphasized direct mail and online sales, often beginning with offers of free trial samples that required only shipping payment via , which transitioned into an auto-ship subscription model instituted in 2001 to ensure recurring deliveries and billing. This approach, while boosting revenue to over $200 million company-wide by 2004 with Enzyte comprising the majority, facilitated unauthorized charges and difficulties in cancellations, elements later scrutinized for their role in misleading consumers. Culturally, the Smilin' Bob persona permeated media as a symbol of bold, humorous supplement , inspiring bootlegged merchandise like T-shirts and unofficial online fan pages by 2004, while reflecting broader anxieties around male performance in American society. The campaign's aggressive tactics and memorable imagery even extended to sponsorships, such as events, underscoring Enzyte's brief dominance before regulatory challenges arose.

Formulation and Ingredients

Primary Components

Enzyte's standard formulation features a blend of natural herbal extracts and minerals, totaling 639 mg per daily serving, designed to support male vitality without incorporating synthetic hormones or prescription drugs. The core ingredients include Asian ginseng root extract (standardized to 7% ), ginkgo leaf extract, , Epimedium sagittatum (horny goat weed) extract, and muira puama extract, each selected for their purported contributions to hormonal and circulatory health based on traditional uses promoted by the manufacturer. Epimedium sagittatum (horny goat weed) is featured for its potential to promote blood flow and erectile function through content, a compound traditionally used in Chinese medicine. Asian ginseng () root extract provides energy and stamina support, with the formula specifying 7% for standardized potency. leaf extract aids circulation by promoting , while offers protection to maintain vascular health. Muira puama extract is included for its traditional use in supporting . Zinc is present at 30 mg per serving to address common deficiencies associated with hormonal imbalances and low testosterone production in men. Additional supporting nutrients like niacin and complement the blend, contributing to overall metabolic and enzymatic functions without exceeding recommended daily allowances. The emphasis on natural herbs underscores Enzyte's positioning as a non-pharmaceutical alternative, with all components sourced from plant-based or origins.

Historical Changes to Formula

Enzyte's original formulation, launched in 2001 by Berkeley Premium Nutraceuticals, included yohimbe bark extract as a key component intended to support male enhancement effects. This ingredient was removed by 2004 in response to advisories highlighting risks such as cardiovascular issues, , and potential interactions with medications, which led to restrictions on yohimbe-containing products in . Concurrent U.S. FDA scrutiny, including reports of adverse events associated with yohimbe in supplements like Enzyte, further prompted the change to mitigate regulatory and safety concerns. After Berkeley Premium Nutraceuticals filed for Chapter 11 bankruptcy in 2008 amid legal challenges, the assets were acquired and restructured under Vianda LLC in 2009, leading to significant updates in the product lineup. Under the new ownership, Enzyte was reformulated with a revised blend emphasizing ingredients like horny goat weed, Asian ginseng, and to maintain its core purpose while aligning with evolving regulatory standards. Subsequent introductions included variants such as Enzyte3 around 2015, which added L-citrulline—a precursor to L-arginine—to enhance production and blood flow support, alongside traditional herbs for a of enhancement, endurance, and energy. Similarly, Enzyte MRC (Male Refueling Complex) was developed as a complementary formula featuring seed extract (standardized to 50% ) for vitality and testosterone level maintenance, combined with and N-acetyl-L-cysteine to address energy and stress factors in men. By 2025, Enzyte products sold by Vianda LLC continue to rely on herb-based compositions, with some variants incorporating L-arginine directly or via precursors like L-citrulline to bolster pathways, while avoiding major synthetic additives to preserve status. These modifications reflect ongoing efforts to ensure compliance with FDA guidelines under the Dietary Supplement Health and Education Act, preventing reclassification as pharmaceuticals and addressing prior enforcement actions related to .

Scientific Assessment

Evidence of Effectiveness

Enzyte is classified as a under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which exempts such products from pre-market FDA approval for efficacy or safety. As a result, Enzyte has not undergone FDA-mandated clinical trials to substantiate its claims of enhancing erectile function or penis size. Scientific evidence supporting Enzyte's effectiveness remains limited, relying primarily on anecdotal user reports rather than rigorous . No peer-reviewed randomized controlled trials (RCTs) have demonstrated that Enzyte promotes or provides sustained improvements in quality. A 2002 review by urologist Kenneth Goldberg, medical director of the Male Health Center, concluded that the product's claims lack medical basis, stating there is no physiological mechanism by which increased blood flow from its ingredients could permanently enlarge the . Independent analyses, such as those from the McGill Office for Science and , reinforce that while some ingredients may temporarily boost blood flow, this does not translate to size increases or lasting enhancements. Studies on Enzyte's key ingredients, such as (included in earlier formulations), yield mixed results for and erectile function but show no evidence of . A 2017 randomized placebo-controlled trial published in Maturitas found that supplementation improved overall sexual function scores in men with mild to moderate after 12 weeks, though effects were modest and not universal. A May 2025 systematic review and meta-analysis of 10 clinical trials reported improvements in with supplementation, highlighting more consistent benefits across studies while noting variability and no impact on penile dimensions or testosterone levels in most cases. The broader medical consensus, including from the American Urological Association (AUA), holds that no dietary supplements reliably enhance size, with any perceived benefits likely attributable to effects. The AUA's guidelines on emphasize evidence-based treatments like phosphodiesterase-5 inhibitors over unproven supplements, and affiliated resources from the Care Foundation state that non-surgical methods, including pills, lack proven efficacy for augmentation. Similarly, the asserts that male enhancement pills do not increase size, based on the absence of supporting scientific data.

Safety and Side Effects

Enzyte, as a , has not been evaluated by the U.S. (FDA) for or prior to , in line with regulations that do not require pre-market approval for such products. This lack of FDA oversight means potential health risks, including unknown long-term effects, remain unverified, with the agency issuing general warnings about sexual enhancement supplements containing unproven ingredients. As of November 2025, Enzyte continues to be sold without FDA approval, and consumers are advised to approach it cautiously due to these unresolved concerns. Potential interactions with medications are a key concern, particularly from ingredients like , which may increase bleeding risk when combined with blood thinners such as by inhibiting platelet aggregation. Asian ginseng, another component, can also interact with anticoagulants or antiplatelet drugs, potentially altering their effects and leading to complications in individuals with cardiovascular conditions. Users with pre-existing health issues, especially heart conditions, are strongly recommended to consult a physician before use to avoid adverse interactions. Reported side effects from Enzyte are often mild and attributed to its stimulant-like ingredients, such as headaches, , flushing, and from Asian . More serious adverse effects have been documented in case reports, including acute confirmed by in one instance, which resolved upon discontinuation of the supplement. Earlier formulations containing yohimbe (prior to 2004) were linked to rare but severe issues like and anxiety due to yohimbe's sympathomimetic properties. Regulatory actions have addressed specific risks, notably Health Canada's 2004 restrictions on yohimbe in natural health products, prompting the removal of this ingredient from Enzyte to comply with unclear and concerns in . The FDA has not issued product-specific recalls for Enzyte but maintains warnings on undeclared or risky ingredients in similar supplements, emphasizing the absence of widespread data. A clinical study further highlighted cardiac risks, showing Enzyte prolonged the QTc interval by up to 37 ms in healthy young men, increasing the potential for and sudden cardiac events, particularly in vulnerable populations. User experiences, as reflected in medical literature rather than anecdotal forums, often include digestive upset alongside the lack of intended benefits, with isolated reports underscoring the need for medical consultation, especially for those with heart conditions, to mitigate risks like . No broad recalls have occurred, but the cumulative evidence from case studies and regulatory alerts reinforces caution in its use.

Federal Indictment

In March 2005, federal agents from the FBI, along with local authorities, raided the headquarters and two other locations of Berkeley Premium Nutraceuticals in , , seizing documents, computers, and other assets as part of an investigation into alleged consumer fraud related to the and sales of Enzyte. The investigation culminated in a federal on September 21, 2006, in the U.S. District Court for the Southern District of , charging Berkeley Premium Nutraceuticals, CEO Steven Warshak, his mother Harriet Warshak (a company consultant), and five other executives and affiliates with a total of 112 counts, including to commit mail fraud, wire fraud, and , as well as and related offenses. The alleged that the scheme defrauded consumers and financial institutions of at least $100 million between 2001 and 2006 through deceptive practices tied to Enzyte sales. Key allegations centered on misleading that promoted Enzyte as a natural male enhancement product capable of increasing size and improving sexual performance, claims that were unsubstantiated by , and a covert "auto-ship" billing program. Under this program, customers who responded to free-trial offers or money-back guarantees were automatically enrolled in monthly shipments without clear disclosure or , resulting in unauthorized charges of approximately $93 per month to their credit cards for products they did not order or receive. The further accused the defendants of using wire transfers and services to execute the , including processing returns only after customers disputed charges, while continuing to ship and bill for additional products. In the lead-up to trial, federal authorities obtained a court order freezing approximately $25 million in assets belonging to Steven Warshak and his family members to prevent dissipation of proceeds from the alleged fraud. This action, combined with the seizure of company records during the 2005 raid, formed the basis for the extensive charges and ensured preservation of evidence and funds for potential restitution.

Trial, Conviction, and Sentencing

The trial of Steven Warshak, his mother Harriet Warshak, and executives from Berkeley Premium Nutraceuticals commenced on , 2008, in the U.S. District Court for the Southern District of in before Judge S. . The proceedings lasted approximately six weeks and centered on evidence of fraudulent marketing schemes, including the use of auto-ship programs and deceptive advertising for Enzyte that misled consumers about the product's and billing practices. Prosecutors presented testimony from former employees and customers detailing how the company processed unauthorized charges and ignored refund requests, defrauding consumers of over $100 million. On February 22, 2008, the jury delivered its verdicts following deliberations, finding Steven Warshak guilty on all 93 counts charged against him, which included one count of , 12 counts of mail fraud, 12 counts of wire fraud, 12 counts of , 55 counts of , and 11 related counts. Harriet Warshak was convicted on four counts: to commit mail and wire fraud, , and . Berkeley Premium Nutraceuticals was also convicted on the count and several fraud-related charges. Sentencing occurred on August 27, 2008. Steven Warshak received 25 years in , five years of supervised release, a $93,000 fine, and was ordered to pay $500 million in restitution to victims. Harriet Warshak was sentenced to two years in and held jointly liable for the restitution. The court further mandated that Berkeley Premium Nutraceuticals and the individual defendants forfeit over $500 million in assets derived from the , including company funds and properties, which precipitated the company's filing and subsequent dissolution. In 2012, the U.S. Department of announced the return of approximately $24 million to victims of the Berkeley as part of the restitution efforts. The Warshaks appealed their convictions and sentences to the U.S. Court of Appeals for the Sixth Circuit. In a December 2010 ruling, the court affirmed Steven Warshak's convictions but vacated his sentence due to an erroneous calculation of the fraud's loss amount and remanded for resentencing; it also reversed two of Harriet Warshak's convictions while upholding the others. On September 20, 2011, upon resentencing, Steven Warshak's term was reduced to 10 years in (with credit for ), from which he was released in 2015 after serving more than seven years. Harriet Warshak's sentence was reduced to , equivalent to one day, given her age and the reversal of key counts.

Company Evolution

Founding and Early Operations

Enzyte was launched in the latter half of 2001 by Berkeley Premium Nutraceuticals, Inc., a company founded that same year by Steven Warshak in , . Warshak, a Cincinnati native with a background in marketing, started the venture in his basement alongside four friends and relatives, initially focusing on herbal supplements as part of a broader portfolio that included products like Avlimil for . As the founder and CEO, Warshak positioned Berkeley as an innovative firm, emphasizing natural alternatives to prescription medications. Berkeley's early business model relied on direct-to-consumer sales through infomercials, television advertisements, and its website, leveraging aggressive marketing to promote Enzyte as a male enhancement supplement. Warshak pioneered e-commerce strategies, including "continuity" subscription billing that automatically charged customers monthly after an initial free trial, which captured credit card information via direct-response ads on networks like CNN and ESPN. This approach, combined with the iconic "Smilin' Bob" campaign, drove rapid growth; by 2004, the company had scaled to employ over 1,400 people working round-the-clock shifts and handling up to 65,000 customer calls per day. Under Warshak's leadership, Berkeley expanded its operations internationally before the government raid on its facilities, while annual revenues reached approximately $250 million by the end of 2004, with Enzyte accounting for the majority. The company's success stemmed from Warshak's vision of democratizing access to wellness products through online and media channels, transforming a small startup into a multimillion-dollar enterprise within a few years.

Bankruptcy, Acquisition, and Current Status

Following the federal convictions and substantial fines in 2008, Berkeley Premium Nutraceuticals, the original manufacturer of Enzyte, filed for bankruptcy. In December 2008, the company's assets were auctioned and acquired by Pristine Bay LLC, an investment firm affiliated with the building's landlord, for $2.75 million, allowing operations to continue under new ownership. This acquisition marked a pivotal restructuring, shifting the company away from its prior leadership and legal troubles. In June 2009, Pristine Bay LLC rebranded the entity as Vianda, LLC, operating under the trade name Vianda | Advancing Wellness for Life, with a focus on regulatory compliance and product quality. The recovery phase saw rapid expansion as sales projections were revised upward. Cheryl Jaeger, who joined the company in 2004 as controller and became acting CEO in 2013, assumed full leadership as CEO in January 2015, overseeing further stabilization efforts such as passing an FDA inspection without observations. Under her tenure, Vianda relocated its headquarters to 9898 Windisch Road, West Chester, Ohio 45069, emphasizing natural, drug-free supplements. As of 2025, Vianda continues to actively market and sell Enzyte along with variants such as Enzyte3 through its official website viandalife.com and platforms like Amazon, with pricing ranging from $35 for a 1-month supply (30 capsules) to $312 for a 12-month supply (360 capsules). The company reports no new legal issues and maintains compliance with FDA regulations for dietary supplements, which do not require pre-market approval but mandate accurate labeling and substantiated claims. Recent consumer reviews in 2025 note steady sales of the product line, though they often highlight the lack of scientific proof for its efficacy claims, aligning with the company's positioning of Enzyte as a natural, non-pharmaceutical option for male vitality support.

References

  1. https://www.amazon.com/Enzyte%25C2%25AE-Natural-Enhancement-Supplement-Quality/dp/B07WK4PRG9
  2. https://www.latimes.com/archives/la-xpm-2007-sep-17-he-skeptic17-story.html
  3. https://oag.ca.gov/news/press-releases/attorney-general-lockyer-announces-settlement-requiring-maker-smiling-bob
  4. https://www.nutraingredients.com/Article/2008/02/26/smiling-bob-legal-action-comes-to-an-end/
  5. https://www.cincinnati.com/story/money/2025/07/21/where-is-steve-warshak-founder-of-berkeley-premium-nutraceuticals/84330852007/
  6. https://www.gs-legal.com/success/parker-v-berkeley-premium-nutraceuticals-inc-enzyte/
  7. https://www.reuters.com/article/business/healthcare-pharmaceuticals/ed-supplement-causes-worrisome-heartbeat-changes-idUSTRE67B3JF/
  8. https://www.gq.com/story/smilin-bob-enzyte-steve-warshak-male-enhancement
  9. https://www.eff.org/files/warshak_opinion_121410.pdf
  10. https://www.nbcnews.com/health/health-news/states-hope-put-frown-smiling-bobs-face-flna1c9442284
  11. https://slate.com/technology/2013/08/enzyte-steven-warshak-the-surprising-case-that-helped-improve-email-privacy.html
  12. https://abcnews.go.com/Primetime/Health/story?id=814864&page=1
  13. https://www.adweek.com/brand-marketing/enzyte-maker-sued-over-ad-claims-72322/
  14. https://www.uspharmacist.com/article/dangers-of-sexual-enhancement-supplements
  15. https://www.opn.ca6.uscourts.gov/opinions.pdf/10a0377p-06.pdf
  16. https://www.opn.ca6.uscourts.gov/opn.ca6.uscourts.gov/opinions.pdf/10a0377p-06.pdf
  17. https://api.ods.od.nih.gov/dsld/s3/pdf/249758.pdf
  18. https://www.canada.ca/en/news/archive/2006/04/health-canada-advises-consumers-not-use-unapproved-products-containing-yohimbine-yohimbe-bark-including-strauss-energy-six-capsules.html
  19. https://www.nutraingredients.com/Article/2018/02/28/Health-Canada-issues-warning-about-product-containing-yohimbe/
  20. https://www.fda.gov/media/128561/download
  21. https://insights.citeline.com/PS102110/Berkeley-Premium-bankrupt/
  22. https://www.bizjournals.com/cincinnati/stories/2009/06/29/story12.html
  23. https://www.amazon.com/Enzyte3%25C2%25AE-Mens-Vitality-Performance-Support/dp/B012DZDZSI
  24. https://enzytemrc.com/ingredients/
  25. https://www.walmart.com/ip/Enzyte-MRC-Male-Refueling-Complex-Testosterone-Support-Vascularity-Energy-Muscle-Strength-Stamina-Increase-Workout-Capacity-Men-Formulated-Fenugreek/157408595
  26. https://www.wired.com/2011/12/st-whatsinside-enzyte-2/
  27. https://www.rangeme.com/brands/vianda
  28. https://www.supplementcritique.com/enzyte-review/
  29. https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements
  30. http://noticias.uol.com.br/midiaglobal/usatoday/2002/04/19/americanos-compram-medicamento-que-promete-aumentar-o-tamanho-do-penis.htm
  31. https://www.mcgill.ca/oss/article/uncategorized/penis-problems
  32. https://www.sciencedirect.com/science/article/abs/pii/S0378512216302973
  33. https://www.nature.com/articles/s41443-025-01086-7
  34. https://examine.com/supplements/tribulus-terrestris/
  35. https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline
  36. https://www.urologyhealth.org/urology-a-z/p/penile-augmentation
  37. https://www.mayoclinic.org/healthy-lifestyle/sexual-health/in-depth/penis/art-20045363
  38. https://www.webmd.com/vitamins/ai/ingredientmono-333/ginkgo
  39. https://www.webmd.com/diet/supplement-guide-ginseng
  40. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/775580
  41. https://pubmed.ncbi.nlm.nih.gov/20861797/
  42. https://www.nsnews.com/living/health-canada-recalls-unauthorized-products-that-may-contain-dangerous-ingredients-3116713
  43. https://www.upi.com/Top_News/2005/03/16/Feds-raid-Enzyte-makers-offices/59401111020021/
  44. https://www.supplysidesj.com/supplement-regulations/feds-raid-berkeley-nutraceuticals
  45. https://www.nbcnews.com/id/wbna14944410
  46. https://www.lexplug.com/casebrief/united_states_v_warshak_659b3008da04d41241e16398
  47. https://www.wired.com/2013/12/dirtbags-enhanced-your-rights/
  48. https://www.jenner.com/a/web/aVyFiEHezU62iSXgcdgbVz/4HRMZQ/United_States_v._Warshak.pdf?1317925457
  49. https://www.nbcnews.com/id/wbna22575047
  50. https://www.supplysidesj.com/supplement-regulations/berkeley-chief-employees-indicted-on-criminal-charges
  51. https://www.foxnews.com/story/natural-male-enhancement-company-owner-indicted-on-fraud-other-charges
  52. https://www.latimes.com/archives/la-xpm-2008-aug-28-fi-enzyte28-story.html
  53. https://www.justice.gov/archive/usao/ohs/news/05-08-12.html
  54. https://www.seattletimes.com/nation-world/smiling-bob-pill-firm-owner-found-guilty-of-fraud/
  55. https://www.cleveland.com/business/2010/12/sentence_tossed_for_ohio_suppl.html
  56. https://www.fox19.com/story/15502672/ohio-supplement-co-founder-to-ask-for-lower-term/
  57. https://viandalife.com/our-roots/
  58. https://viandalife.com/
  59. https://viandalife.com/enzyte/
  60. https://www.amazon.com/Enzyte%25C2%25AE-Doctor-Formulated-Natural-Enhancement-Ginseng/dp/B00M8ECQH6
Add your contribution
Related Hubs
User Avatar
No comments yet.